Cargando…

Liver injury in children: signal analysis of suspected drugs based on the food and drug administration adverse event reporting system

BACKGROUND: Evidence of drug-induced liver injury is abundant in adults but is lacking in children. Our aim was to identify suspected drug signals associated with pediatric liver injury. METHODS: Hepatic adverse events (HAEs) among children reported in the Food and Drug Administration Adverse Event...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yan, Li, Hailong, Huang, Liang, Wan, Chaomin, Wang, Huiqing, Jiao, Xuefeng, Zeng, Linan, Jia, Zhijun, Cheng, Guo, Zhang, Lei, Zhang, Wei, Zhang, Lingli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537493/ https://www.ncbi.nlm.nih.gov/pubmed/37770847 http://dx.doi.org/10.1186/s12887-023-04097-9

Ejemplares similares

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database
por: Li, Hailong, et al.
Publicado: (2023)

Cosmetics and Cancer: Adverse Event Reports Submitted to the Food and Drug Administration
por: Jacob, Saya L, et al.
Publicado: (2018)

Prevention of adverse events in the administration of drugs
por: Diano, G, et al.
Publicado: (2010)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
por: Zhang, Ying, et al.
Publicado: (2023)

Mortality and oral anticoagulants in the Food and Drug Administration Adverse Event Reporting System
por: Serebruany, Victor, et al.
Publicado: (2017)

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
por: Wang, Jun, et al.
Publicado: (2023)

Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration’s Adverse Event Reporting System Narratives
por: Polepalli Ramesh, Balaji, et al.
Publicado: (2014)

Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and Underreporting
por: Serebruany, Victor L., et al.
Publicado: (2017)

Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database
por: Toki, Tadashi, et al.
Publicado: (2018)

Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017
por: Dores, Graça M., et al.
Publicado: (2019)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Reporting adverse drug events to the Therapeutic Goods Administration
por: Martin, Jennifer H, et al.
Publicado: (2021)

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
por: Kato, Yamato, et al.
Publicado: (2015)

Recombinant mycobacterium tuberculosis fusion protein for diagnosis of mycobacterium tuberculosis infection: a short-term economic evaluation
por: Liu, Zheng, et al.
Publicado: (2023)

Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database
por: Nagai, Junko, et al.
Publicado: (2021)

Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
por: Wang, Yu, et al.
Publicado: (2020)

Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration
por: Lipner, Shari R., et al.
Publicado: (2020)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

PSAT122 The Changing Face of Drug-Induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Dalmazi, Guido D, et al.
Publicado: (2022)

Systematic review of the prevalence and nature of drug‐related problems in paediatric patients
por: Mi, Xue, et al.
Publicado: (2022)

Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis
por: Zhou, Zeyun, et al.
Publicado: (2020)

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021
por: Learned, Christine, et al.
Publicado: (2022)

Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System
por: Naganuma, Misa, et al.
Publicado: (2019)

Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986–2019
por: Wei, Shaokui, et al.
Publicado: (2021)

Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system
por: Wu, Ziyang, et al.
Publicado: (2022)

Detecting associations between behavioral addictions and dopamine agonists in the Food & Drug Administration’s Adverse Event database
por: Gendreau, Katherine E., et al.
Publicado: (2014)

Case series of reports of pruritus and sipuleucel-T submitted to the Food and Drug Administration Adverse Event Reporting System
por: Dores, Graça M., et al.
Publicado: (2019)

Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration
por: Qian, Jingjing, et al.
Publicado: (2022)

Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
por: Matsumoto, Kiyoka, et al.
Publicado: (2020)

Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database
por: Shimada, Kazuyo, et al.
Publicado: (2019)

Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system
por: Wei, Wei, et al.
Publicado: (2023)

Analysis of Adverse Events and Medical Errors in Long-Term Hormone Treatments for Endometriosis: A Study Based on the US Food and Drug Administration Event Reporting System
por: Zhang, Yuxin, et al.
Publicado: (2022)

Arrhythmic events associated with immune checkpoint inhibitors therapy: A real‐world study based on the Food and Drug Administration Adverse Event Reporting System database
por: Liu, Yunwei, et al.
Publicado: (2022)

Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)
por: Hoffman, Keith B., et al.
Publicado: (2014)

Global COVID‐19 pandemic and reporting behavior ‐ An analysis of the Food and Drug Administration adverse events reporting system
por: Dörks, Michael, et al.
Publicado: (2021)

Adverse events related to total ankle replacement devices: an analysis of reports to the United States Food and Drug Administration
por: Mahmoud, Karim, et al.
Publicado: (2021)

Safety signals of albumin-bound paclitaxel: Data mining of the Food and Drug Administration adverse event reporting system
por: Wang, Yuwei, et al.
Publicado: (2023)

An evaluation of adverse drug reactions and outcomes attributed to kratom in the US Food and Drug Administration Adverse Event Reporting System from January 2004 through September 2021
por: Li, Xiaotong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gva5vaak9hlch0c97nlj7ubh0n